Effects of HCV treatment on cytokine expression during HCV/HIV coinfection

• Published in: Journal of interferon & cytokine research Vol. 26; no. 11; pp. 834 - 838
• Main Authors: Blackard, Jason T, Kang, Minhee, Sherman, Kenneth E, Koziel, Margaret James, Peters, Marion G, Chung, Raymond T
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc 01.11.2006
• Subjects: Adult; Cytokines - blood; Female; Gene Expression Regulation; Hepatitis C - blood; Hepatitis C - complications; Hepatitis C - therapy; Hepatitis C virus; HIV Infections - blood; HIV Infections - complications; HIV Infections - therapy; Human immunodeficiency virus; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies
• ISSN: 1079-9907; 1557-7465
• DOI: 10.1089/jir.2006.26.834

There is growing evidence that cytokine expression is linked to hepatitis C virus (HCV) pathogenesis and treatment response rates among HCV-monoinfected persons. However, because of the profound effects of human immunodeficiency virus (HIV) coinfection on HCV, it is not clear if these observations are also true for HCV/HIV-coinfected individuals. Serum expression of the proinflammatory cytokines interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-alpha) and the fibrogenic cytokine transforming growth factor-beta1 (TGF-beta1) were measured in HCV/HIV-coinfected persons at baseline and at week 24 of HCV therapy. Higher levels of IL-8 and TGF-beta were demonstrated among nonwhite subjects at baseline. Increases in TNF-alpha and IL-8 expression were found at week 24 of HCV therapy, suggesting that enhanced proinflammatory cytokine production may occur during HCV treatment. However, cytokine levels were not predictive of HCV virologic, biochemical, or histologic response. Although previous studies conducted among HCV-monoinfected individuals have suggested that cytokine levels could predict the virologic response to therapy, no such associations were observed among HCV/HIV-coinfected persons, suggesting that they may respond differently to treatment than do their HCV-monoinfected counterparts.